
FIREBRICK PHARMA LIMITED
ACN 157 765 896
NOTICE OF GENERAL MEETING

Notice is given that the Meeting will be held at:

TIME: 11.00am (AEST)
DATE: Monday, 22 June 2026
PLACE: by Virtual Meeting Facility

The Company is pleased to provide Shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic, where Shareholders will be able to watch, listen, and vote online.

Details on how to access the virtual Meeting are set out in this Notice.

For the purpose of Section 249RA of the Corporations Act, the place at which the Meeting of the Company is held is taken to be:

Level 10, 440 Collins Street, Melbourne, Victoria.

The business of the Meeting affects your shareholding and your vote is important.

This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 11.00am (AEST) on Saturday, 20 June 2026.

NOTICE OF GENERAL MEETING

Notice is given that a General Meeting of the Shareholders of Firebrick Pharma Limited (the **Company**) will be held through the Virtual Meeting Facility on Monday, 22 June 2026 commencing at 11.00am (AEST) (the **Meeting**).

Through the Virtual Meeting Facility, Shareholders will be able to participate in the meeting by listening, asking questions and voting on the resolutions. Shareholders are strongly encouraged to cast their vote by proxy prior to the Meeting in accordance with the instructions set out on page 6 of this Notice to ensure their votes are counted. Further information on how to participate and vote during the Meeting via the Virtual Meeting Facility is set out on page 5 of this Notice.

The Explanatory Statement that accompanies this Notice provides additional information on the matters to be considered at the Meeting. The Explanatory Statement and Proxy Form are part of this Notice.

Should circumstances further change between the date of this Notice of Meeting and the proposed time of the Meeting, the Directors will further update Shareholders with the proposed next steps.

BUSINESS OF THE MEETING

AGENDA

1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES TO PHARMA NUTRIA N.A. INC – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 16 October 2025 of 1,200,000 fully paid ordinary Shares to Pharma Nutria N.A. Inc at an issue price of \$0.085 (8.5 cents), on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

2. RESOLUTION 2 – RATIFICATION OF PRIOR ISSUE OF INCENTIVE OPTIONS TO AL MOGHADDAM

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 10 February 2026 of 1,000,000 Incentive Options, on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

3. RESOLUTION 3 – RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT SHARES – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 17 April 2026 of 6,877,764 fully paid ordinary Shares at an issue price of \$0.047 (4.7 cents), on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

4. RESOLUTION 4 – RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT SHARES – LISTING RULE 7.1A

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 21,276,603 fully paid ordinary Shares on 13 April 2026 and 3,760,533 fully paid Shares on 17 April 2026 at an issue price of \$0.047 (4.7 cents), on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

5. RESOLUTION 5 – RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT OPTIONS – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 10,638,304 Placement Options on 13 April 2026 and 5,319,145 Placement Options on 17 April 2026, on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

6. RESOLUTION 6 – RATIFICATION OF PRIOR ISSUE OF BROKER OPTIONS TO SP CORPORATE ADVISORY PTY LTD – LISTING RULE 7.1

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 20 April 2026 of 6,382,980 Broker Options, on the terms and conditions as set out in the Explanatory Statement.”

A voting exclusion statement applies to this Resolution. Please see below.

Dated: 18 May 2026

By order of the Board

S Buckley

**Stephen Buckley
Company Secretary**

Voting Exclusion Statements

In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the resolution set out below by or on behalf of the following persons:

Resolution 1 – Ratification of Prior Issue of Placement Shares to Pharma Nutria N.A. Inc – Listing Rule 7.1	The Company will disregard any votes cast in favour of this Resolution 2 by Pharma Nutria N.A. Inc or any associates of Pharma Nutria N.A. Inc.
Resolution 2 – Ratification of Prior Issue Incentive Options to Al Moghaddam	The Company will disregard any votes cast in favour of this Resolution 2 by Al Moghaddam or any associates of Al Moghaddam.
Resolution 3 – Ratification of Prior Issue of March Placement Shares – Listing Rule 7.1	The Company will disregard any votes cast in favour of this Resolution 3 by or on behalf of any person who participated in the issue of securities, or any associates of that person or those persons.
Resolution 4 – Ratification of Prior Issue of March Placement Shares – Listing Rule 7.1A	The Company will disregard any votes cast in favour of this Resolution 4 by or on behalf of any person who participated in the issue of securities, or any associates of that person or those persons.
Resolution 5 – Ratification of Prior Issue of March Placement Options – Listing Rule 7.1	The Company will disregard any votes cast in favour of this Resolution 5 by or on behalf of any person who participated in the issue of securities, or any associates of that person or those persons.
Resolution 6 – Ratification of Prior Issue of Broker Options to SP Corporate Advisory Pty Ltd – Listing Rule 7.1	The Company will disregard any votes cast in favour of this Resolution 6 by SP Corporate Advisory Pty Ltd or any associates of SP Corporate Advisory Pty Ltd.

However, this does not apply to a vote cast in favour of the Resolution by:

- a) a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - (ii) the holder votes on the Resolution in accordance with the directions given by the beneficiary to the holder to vote in that way.

How to vote and ask questions

The Company has decided to hold the Meeting as a virtual meeting. You may vote by proxy, personal representative or via the Virtual Meeting Facility.

Shareholders will be able to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business at the conclusion of the Meeting.

Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to the Company Secretary at cosec@firebrickpharma.com at least 48 hours before the Meeting.

Voting by proxy

The Company intends to conduct the Meeting virtually via Automic's online meeting platform. Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the Chair as early as possible and in any event prior to the cut-off for proxy voting as set out in the Notice. Proxy forms can be lodged as below:

- By following the directions on the Proxy Form;
- By scan and email to meetings@automicgroup.com.au;
- In person at Automic, Level 5, 126 Phillip Street, Sydney NSW 2000;
- By post to Automic, GPO Box 5193, Sydney NSW 2001; or
- By facsimile to +61 (0)2 8583 3040.

All proxy forms must be received by the Company not later than **11.00am (AEST) on Saturday, 20 June 2026**.

In accordance with section 249L of the Corporations Act, Shareholders are advised that:

- each Shareholder has a right to appoint a proxy;
- the proxy need not be a Shareholder of the Company; and
- a Shareholder who is entitled to cast 2 or more votes may appoint 2 proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the member appoints 2 proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes.

In addition:

- if a proxy is given by a body corporate, a Proxy Form must be executed in writing under the common seal of the corporation or otherwise in accordance with section 127 of the Corporations Act or signed by an attorney;
- if a proxy is given by a natural person, a Proxy Form must be executed under the hand of that person or that person's attorney;
- to be effective, the Proxy Form and the power of attorney or other authority (if any) under which it is signed or a certified copy, must be received by the Company at least 48 hours before the time for holding the Meeting or any adjourned Meeting;
- if a Shareholder appoints the Chair as the Shareholder's proxy and does not specify how the Chair is to vote, the Chair will vote, as proxy for that Shareholder, in favour of or against each resolution as set out in the Explanatory Statement;
- a Shareholder that is a body corporate may appoint an individual as its representative to exercise all or any of the powers the body corporate may exercise at the Meeting (the appointment may be a standing one); and
- any Proxy Form received after this deadline will be treated as invalid.

Personal Representative

To vote by personal representative, please forward the authority under which the personal representative has been appointed (or a certified copy of the authority) to the address set out above for the return of Proxy Forms so that it is received no later than **11.00am (AEST) on Saturday, 20 June 2026**.

Corporate Representative

Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company's representative. The authority may be sent to the Company and/or Share Registry in advance of the Meeting. An appointment of corporate representative form can be obtained by via the Company's share registry website – www.automicgroup.com.au.

Preparing to attend the Virtual Meeting

The company is pleased to provide shareholders with the opportunity to attend and participate in the Meeting through an online meeting platform powered by Automic.

Shareholders that have an existing account with Automic will be able to watch, listen and vote online.

Shareholders who do not have an account with Automic are strongly encouraged to register for an account **as soon as possible and well in advance of the Meeting** to avoid any delays on the day of the Meeting.

An account can be created via the following link investor.automic.com.au and then clicking on **“Register”** and following the prompts.

Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic.

Attending and Voting at the Virtual Meeting

Shareholders who wish to vote virtually on the day of the AGM can do so by logging in to the Automic shareholder portal:

1. Open your internet browser and go to investor.automic.com.au
2. Login using your username and password. If you do not already have an account, click **“Register”** and follow the prompts. **Shareholders are encouraged to register prior to the commencement of the Meeting to avoid delays in accessing the virtual platform.**
3. After logging in, a banner will appear at the bottom of your screen when the Meeting is open for registration. Click **“Register”**. Alternatively, select Meetings from the left-hand menu.
4. Click on **“Join Meeting”** and follow the prompts.
5. When the Chair of the Meeting declares the poll open, select the **“Voting”** dropdown menu on the right-hand side of your screen.
6. Select either the **“Full”** or **“Allocate”** option to access your electronic voting card.
7. Follow the prompts to record your voting direction for each resolution and click **“Submit votes”**. For allocated votes, the number of votes submitted must not exceed your remaining available units.

Important: *Votes cannot be amended once submitted.*

For further information on the live voting process please see the **Registration and Voting Guide** at: <https://www.automicgroup.com.au/virtual-agms/>

The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business.

Please note that if you have previously submitted a Proxy Form, your online attendance at the Meeting will revoke your proxy's authority to vote, unless you inform the Company otherwise prior to commencement of the Meeting, in which case, your authority to vote at the Meeting is suspended while your proxy is present.

Should you wish to discuss the matters in this Notice of Meeting please do not hesitate to contact the Company Secretary on (08) 6189 1155.

EXPLANATORY STATEMENT

This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

Shareholders should read this statement and the Notice in full before deciding how to vote on the Resolutions set out in the Notice. All Resolutions to be considered at the Meeting will be decided by poll based on both proxy votes received prior to the commencement of the Meeting and votes cast in person at the physical venue or via the online voting facility during the Meeting. Shareholders are encouraged to cast their vote by proxy prior to the Meeting in accordance with the instructions set out on page 5 of this Notice.

1. RESOLUTION 1 – RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES TO PHARMA NUTRIA N.A. INC – LISTING RULE 7.1

1.1 Background

On 16 October 2025, the Company announced that it had secured a \$102,000 investment from its Philippines business partner, Pharma Nutria N.A., an entity affiliated with the Company's licensing partner in the Philippines, at an issue price of \$0.085 (8.5 cents) per share (**October Placement**) (**October Placement Shares**).

On 16 October 2025 the Company issued 1,200,000 Shares without shareholder approval under the Company's existing placement capacity pursuant to ASX Listing Rules 7.1. There were no adviser or broker fees associated with the October Placement.

Resolution 1 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 1,200,000 October Placement Shares.

1.2 Listing Rules

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

The issue of the October Placement Shares does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rule 7.1 for the 12 month period following the date of the issue.

Under Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of Shareholders for the purposes of Listing Rule 7.1 if the issue did not breach Listing Rule 7.1 at the time and Shareholders subsequently approve it. The Company now seeks Shareholder ratification of the issue of the October Placement Shares pursuant to Listing Rule 7.4 in order to retain the flexibility to issue additional equity securities in the future without having to obtain prior Shareholder approval.

If Resolution 1 is passed, the issue will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the October Placement Shares.

If Resolution 1 is not passed, the issue will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the October Placement Shares.

1.3 Information required by Listing Rule 7.5

Pursuant to and in accordance with ASX Listing Rule 7.5, the following information is provided in relation to Resolution 1:

Listing Rule	Details
7.5.1	The October Placement Shares were issued to Pharma Nutria N.A., Inc an entity associated with Firebrick's licensing partner in the Philippines and a professional investor for the purposes of section 708 of the Corporations Act. The recipient is not a related party of the Company.
7.5.2	1,200,000 October Placement Shares were issued.
7.5.3	The October Placement Shares issued were all fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares.
7.5.4	The October Placement Shares were issued on 16 October 2025.
7.5.5	The Placement Shares were issued at a price of \$0.085 (8.5 cents) per October Placement Share.
7.5.6	The funds raised from this issue were for the purposes of allowing a strategic investor to increase their holding to a substantial holding level above 5% and the funds used have been used for general working capital requirements.
7.5.7	The October Placement Shares were not issued under an agreement.
7.5.8	A voting exclusion statement for this Resolution 1 is included above in this Notice of Meeting.

1.4 Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of Resolution 1.

The Chair of the meeting presently intends to vote undirected proxies in favour of Resolution 1.

2. RESOLUTION 2 - RATIFICATION OF PRIOR ISSUE OF INCENTIVE OPTIONS TO AL MOGHADDAM

2.1 General

On 10 February 2026, the Company announced that Al Moghaddam would be appointed as a non-executive director of the Company, with effect from 1 March 2026. Pursuant to his letter of appointment (**Letter of Appointment**), Mr Moghaddam was issued with 1,000,000 Incentive Options exercisable at \$0.15 per Incentive Option, expiring 10 February 2030.

The Incentive Options were issued utilising the Company's placement capacity under Listing Rule 7.1

The Letter of Appointment is otherwise on terms and conditions considered standard for an appointment of a non-executive director to a public company. The terms of the Incentive Options are set out in Schedule 2.

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue equity securities to:

- 10.11.1 a related party;
- 10.11.2 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the company;
- 10.11.3 a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;
- 10.11.4 an associate of a person referred to in Listing Rules 10.11.1 to 10.11.3; or

10.11.5 a person whose relationship with the company or a person referred to in Listing Rules 10.11.1 to 10.11.4 is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The issue of the Incentive Options falls within ASX Listing Rule 10.12 Exception 12 because at the time that the Letter of Appointment was entered into, Al Moghaddam would not otherwise be a related party of the Company but for the fact that he believes that he is likely to become a related party of the Company in the future because of the Letter of Appointment and as such, approval under ASX Listing Rule 10.11 was not sought for the issue of the Incentive Options.

The Directors determined that the exception in section 211 of the Corporations Act applies in relation to the issue of the Incentive Options to Al Moghaddam, given that the issue is considered reasonable remuneration and prior to Al Moghaddam becoming a Director, and accordingly, Shareholder approval pursuant to section 208 of the Corporations Act was not sought.

Accordingly, Resolution 2 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 1,000,000 Incentive Options.

2.2 Listing Rules

A summary of Listing Rules 7.1 and 7.4 is outlined in Section 1.2 above.

If Resolution 2 is passed, the issue will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the Incentive Options.

If Resolution 2 is not passed, the issue will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the Incentive Options.

2.3 Information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to Listing Rule 7.4:

Listing Rule	Details
7.5.1	The Incentive Options were issued to Al Moghaddam.
7.5.2	1,000,000 Incentive Options were issued.
7.5.3	Terms and Conditions of the Incentive Options issued are set out in Schedule 2.
7.5.4	The Incentive Options were issued on 10 February 2026.
7.5.5 and 7.5.6	The Incentive Options were issued for nil consideration and the Company will only receive funds if the Incentive Options are exercised into Shares. The issue of the Incentive Options was to incentivise Al Moghaddam to take on the role of non-executive director of the Company.
7.5.7	The Incentive Options were issued pursuant to the Letter of Appointment as a non-executive director of the Company.
7.5.8	A voting exclusion statement for Resolution 2 is included above in this Notice of Meeting.

2.4 Directors' Recommendation

The Directors, other than Al Moghaddam who has a personal interest in this Resolution 2, recommend that Shareholders vote in favour of Resolution 2.

The Chair of the meeting intends to vote undirected proxies in favour of Resolution 2.

3. RESOLUTIONS 3, 4 AND 5 - RATIFICATION OF PRIOR ISSUE OF MARCH PLACEMENT SHARES AND MARCH PLACEMENT OPTIONS– LISTING RULE 7.1 AND 7.1A

3.1 Background to March Placement

On 31 March 2026, the Company announced that it had received firm commitments from investors for approximately \$1.5 million through the issue of 31,914,893 Shares at an issue price of \$0.047 (4.7 cents) per Share (**March Placement Shares**), together with one free option for every two March Placement Shares subscribed for and issued, with an exercise price of \$0.095 (9.5 cents) and an expiry date of 4 July 2028 (**March Placement Options**) (**March Placement**).

The \$1.5 million raised from the March Placement will be applied as follows:

- Costs associated with expansion of Business Development & Licensing (BD&L);
- New product development (NPD) costs of two new products; and
- Working Capital up to 12 months.

The March Placement Shares and March Placement Options (together, **March Placement Securities**) were completed on two separate dates, being 13 April 2026 and 17 April 2026 without shareholder approval under the Company's existing placement capacities pursuant to Listing Rules 7.1 and 7.1A as follows:

- (a) 6,877,764 March Placement Shares were issued on 17 April 2026 pursuant to the Company's Listing Rule 7.1 capacity (the subject of Resolution 3);
- (b) 21,276,603 March Placement Shares were issued on 13 April 2026 and 3,760,533 March Placement Shares were issued on 17 April 2026 pursuant to the Company's Listing Rule 7.1A capacity (the subject of Resolution 4); and
- (c) 10,638,304 March Placement Options were issued on 13 April 2026 and 5,319,145 March Placement Options were issued on 17 April 2026 pursuant to the Company's Listing Rule 7.1 capacity (the subject of Resolution 5).

The investors in the March Placement (**March Placement Participants**) were either introduced by SP Corporate Advisory Pty Ltd who acted as Lead Manager or were existing shareholders. SP Corporate Advisory Pty Ltd received a fee of 6% on any funds they raised, along with one Option for every five March Placement Shares issued. The Options are the subject of Resolution 6

Resolution 3 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 6,877,764 March Placement Shares.

Resolution 4 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 25,037,136 March Placement Shares.

Resolution 5 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 15,957,449 March Placement Options.

3.2 Listing Rules

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

Under Listing Rule 7.1A however, an eligible entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%. The Company obtained this approval at its annual general meeting held on 26 November 2025.

The issue of the March Placement Shares and March Placement Options does not fit within any of the exceptions set out in Listing Rule 7.2 and, as it has not yet been approved by Shareholders, it effectively uses up part of the 25% limit in Listing Rules 7.1 and 7.1A, reducing the Company's capacity to issue further equity securities without Shareholder approval under Listing Rules 7.1 and 7.1A for the 12 month period following the date of the issue.

Listing Rule 7.4 provides that where an entity in a general meeting ratifies the previous issue of securities made pursuant to Listing Rule 7.1 (and provided that the previous issue did not breach Listing Rule 7.1), those securities will be deemed to have been made with Shareholder approval under Listing Rule 7.1, thereby “refreshing” the Company’s capacity under Listing Rule 7.1. A note to Listing Rule 7.4 also provides it can also be used to ratify a previous issue of securities made with approval pursuant to Listing Rule 7.1A.

The issue of the March Placement Securities was in accordance with Listing Rules 7.1 and 7.1A and therefore did not breach Listing Rule 7.1 at the time the issue occurred.

By ratifying the issue of the March Placement Shares and March Placement Options, the Company will retain the flexibility to issue equity securities in the future within the limits of Listing Rules 7.1 and 7.1A up to its 25% capacity without needing to seek further Shareholder approval.

Accordingly, the Company seeks Shareholder ratification of the issue of the March Placement Shares and March Placement Options pursuant to Listing Rule 7.4 in order to retain as the flexibility to issue additional equity securities in the future without having to obtain prior Shareholder approval.

3.3 Technical information required by Listing Rule 14.1A

If Resolution 3 is approved, the prior issue of 6,877,764 March Placement Shares will be excluded in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Shares.

If this Resolution 3 is not approved, the prior issue of 6,877,764 March Placement Shares will be included in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Shares.

If Resolution 4 is approved, the prior issue of 25,037,136 March Placement Shares will be excluded in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Shares.

If this Resolution 4 is not approved, the prior issue of 25,037,136 March Placement Shares will be included in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Shares.

If Resolution 5 is approved, the prior issue of 15,957,449 March Placement Options will be excluded in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Options.

If this Resolution 5 is not approved, the prior issue of 15,957,449 March Placement Options will be included in calculating the Company’s 25% limit in Listing Rules 7.1 and 7.1A, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the March Placement Options.

3.4 Information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to Listing Rule 7.4:

Listing Rule	Details
7.5.1	The March Placement Securities were issued to the March Placement Participants, who were either identified through a bookbuild process, which involved SP Corporate Advisory Pty Ltd as Lead Manager seeking expressions of interest to participate in the capital raising from non-related parties of the Company, or were existing shareholders in the Company.

	For the purposes of paragraph 7.4 of ASX Guidance Note 21, the Company notes that neither a related party of the Company, nor any member of the Company's key management personnel, substantial holder in the Company, or adviser to the Company, or any associate of any of these, has taken up more than 1% of the Company's issued capital at the time of the June Placement.
7.5.2	A total of 31,914,900 March Placement Securities were issued as follows: (a) 6,877,764 March Placement Shares were issued on 17 April 2026 pursuant to the Company's placement capacity under Listing Rule 7.1 (the subject of Resolution 3); (b) 21,276,603 March Placement Shares were issued on 13 April 2026 and 3,760,533 March Placement Shares were issued on 17 April 2026 pursuant to the Company's placement capacity under Listing Rule 7.1A (the subject of Resolution 4); and (c) 10,638,304 March Placement Options were issued on 13 April 2026 5,319,145 March Placement Options were issued on 17 April 2026 pursuant to the Company's placement capacity under Listing Rule 7.1 (the subject of Resolution 5).
7.5.3	The March Placement Shares were fully paid ordinary shares in the capital of the Company issued on the same terms and conditions as the Company's existing Shares. Terms and conditions of the March Placement Options issued are set out in Schedule 1.
7.5.4	The March Placement Securities were issued on 13 April 2026 and 17 April 2026 for the purpose of the March Placement.
7.5.5	The March Placement Shares were issued at \$0.047 (4.7 cents) per March Placement Share. The March Placement Options were issued on the basis of one free attaching option for every two March Placement Shares, and were issued with a nil issue price.
7.5.6	The purpose of the issue was to raise funds intended to be applied to: <ul style="list-style-type: none"> • Costs associated with expansion of Business Development & Licensing (BD&L); • New product development (NPD) costs of two new products; and • Working Capital up to 12 months.
7.5.7	The March Placement Securities were not issued under an agreement.
7.5.8	A voting exclusion statement for Resolutions 3, 4 and 5 is included above in this Notice of Meeting.

3.5 Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of Resolutions 3 to 5.

The Chair of the meeting intends to vote undirected proxies in favour of Resolutions 3 to 5.

4. RESOLUTION 6 - RATIFICATION OF PRIOR ISSUE OF BROKER OPTIONS TO SP CORPORATE ADVISORY PTY LTD– LISTING RULE 7.1

4.1 Background

Background to the March Placement is noted in Section 3.1 above.

The investors in the March Placement (**March Placement Participants**) were either introduced by SP Corporate Advisory Pty Ltd who acted as Lead Manager or were existing shareholders. SP Corporate Advisory Pty Ltd received a fee of 6% on any funds they raised, along with one Option for every five March Placement Shares issued.

The Broker Options were issued utilising the Company's placement capacity under Listing Rule 7.1

Accordingly, Resolution 6 seeks Shareholder ratification for the purpose of Listing Rule 7.4 for the issue of the 6,382,980 Broker Options.

4.2 Listing Rules

A summary of Listing Rules 7.1 and 7.4 is set out in Section 1.2 above.

If Resolution 6 is passed, the issue will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the Broker Options.

If Resolution 6 is not passed, the issue will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities that the Company can issue without Shareholder approval over the 12 month period following the date of the issue of the Broker Options.

4.3 Information required by Listing Rule 7.5

Pursuant to and in accordance with Listing Rule 7.5, the following information is provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to Listing Rule 7.4:

Listing Rule	Details
7.5.1	The Broker Options were issued to SP Corporate Advisory Pty Ltd or their associates pursuant to the Lead Manager Mandate as announced to the market on 31 March 2026.
7.5.2	6,382,980 Broker Options were issued.
7.5.3	Terms and Conditions of the Broker Options issued are set out in Schedule 1.
7.5.4	The Broker Options were issued on 20 April 2026.
7.5.5 and 7.5.6	The Broker Options were issued for nil consideration under the Lead Manager Mandate and the Company will only receive funds if the Broker Options are exercised into Shares.
7.5.7	The Broker Options were issued pursuant to the Lead Manager Mandate. Under the Mandate SP Corporate Advisory Pty Ltd received a fee of 6% on any funds they raised plus one Broker Option being issued for every five March Placement Shares issued.
7.5.8	A voting exclusion statement for Resolution 6 is included above in this Notice of Meeting.

4.4 Directors' Recommendation

The Directors unanimously recommend that Shareholders vote in favour of Resolution 6.

The Chair of the meeting intends to vote undirected proxies in favour of Resolution 6.

5. GLOSSARY

\$ means Australian dollars.

AEST means Australian Eastern Standard Time as observed in Melbourne, Victoria.

Associate has the meaning given in the ASX Listing Rules.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

ASX Listing Rules means the Listing Rules of ASX.

Board means the current board of Directors of the Company.

Broker Option has the meaning given to that term in Section 4.1.

Chair means the chair of the Meeting.

Company means Firebrick Pharma Limited (ACN 157 765 896).

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the current directors of the Company.

Explanatory Statement means the explanatory statement accompanying the Notice.

General Meeting or **Meeting** means the meeting convened by the Notice.

Incentive Option has the meaning given to that term in Section 2.1.

March Placement has the meaning given to that term in Section 3.1.

March Placement Participants has the meaning given to that term in Section 3.1.

March Placement Shares has the meaning given to that term in Section 3.1.

March Placement Options has the meaning given to that term in Section 3.1.

Letter of Appointment has the meaning given to that term in Section 2.1.

Listing Rules means the Listing Rules of ASX.

Notice or **Notice of Meeting** means this notice of meeting including the Explanatory Statement and the Proxy Form.

Previous Issue has the meaning given to that term in Section 3.2.

Proxy Form means the proxy form accompanying the Notice.

Related Body Corporate has the meaning given in section 9 of the Corporations Act.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Section means a section of the Explanatory Statement.

Security means an Equity Security or a Debt Security.

Equity Security means:

- (a) a Share;
- (b) a unit;
- (c) an option over an issued or unissued share or unit;
- (d) a right to an issued or unissued share or unit;
- (e) an option over, or right to, a security referred to in (c) or (d) above;
- (f) a convertible security;
- (g) any security that ASX decides to classify as an equity security;
- (h) but not a security ASX decides to classify as a debt security.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

Share Registry means Automatic Registry Services.

Virtual Meeting Facility means the online meeting platform powered by Automatic Group.

SCHEDULE 1: TERMS AND CONDITIONS OF MARCH PLACEMENT OPTIONS AND BROKER OPTIONS

1.	Entitlement	Subject to paragraph 12, Each Option entitles the holder to subscribe for one Share upon exercise of the Option.
2.	Exercise Price	Subject to paragraph 9, the amount payable upon exercise of each Option will be \$0.095 (Exercise Price).
3.	Expiry Date	Each Option will expire at 5:00 pm (AEST), 4 July 2028(Expiry Date). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date
4.	Exercise Period	The Options are exercisable at any time on or prior to the Expiry Date (Exercise Period).
5.	Exercise Notice	The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (Exercise Notice) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.
6.	Exercise Date	An Exercise Notice is only effective on and from the later of the date of receipt of the Exercise Notice and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (Exercise Date).
7.	Timing of issue of Shares on exercise	<p>Within five Business Days after the Exercise Date, the Company will:</p> <ul style="list-style-type: none"> (a) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Exercise Notice and for which cleared funds have been received by the Company; (b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and (c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options. <p>If a notice delivered under 7(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.</p>
8.	Shares issued on exercise	Shares issued on exercise of the Options rank equally with the then issued shares of the Company.
9.	Reorganisation	If there is a reorganisation of the issued share capital of the Company (including any subdivision, consolidation, reduction, return or cancellation of such issued capital of the Company), the rights of the holder will be changed to the extent necessary to comply with the ASX Listing Rules applicable to a reorganisation of capital at the time of the reorganisation.
10.	Participation in new issues	There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of

		capital offered to Shareholders during the currency of the Options without exercising the Options.
11.	Change in exercise price/Adjustment for rights issue	An Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.
12.	Adjustment for bonus issues of Shares	<p>If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment):</p> <p>(a) the number of Shares or other securities which must be issued on the exercise of an Option will be increased by the number of Shares or other securities which the holder would have received if the holder had exercised the Option before the record date for the bonus issue; and</p> <p>(b) no change will be made to the Exercise Price.</p>
13.	Transferability	The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

SCHEDULE 2: TERMS AND CONDITIONS OF INCENTIVE OPTIONS

1.	Entitlement	Subject to paragraph 12, Each Option entitles the holder to subscribe for one Share upon exercise of the Option.
2.	Exercise Price	Subject to paragraph 9, the amount payable upon exercise of each Option will be \$0.15 (Exercise Price).
3.	Expiry Date	Each Option will expire at 5:00 pm (AEST), 1 August 2029 (Expiry Date). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date
4.	Exercise Period	The Options are exercisable at any time on or prior to the Expiry Date (Exercise Period).
5.	Exercise Notice	The Options may be exercised during the Exercise Period by notice in writing to the Company (Notice of Exercise) and payment of the Exercise Price for each Option being exercised in Australian currency by electric funds transfer or other means of payment acceptable to the Company. Any Notice of Exercise of an Option received by the Company will be deemed to be effective notice of the exercise of that Option on and from the date of receipt of the Notice of Exercise and the receipt of the full amount of the Exercise Price for each Option exercised in cleared funds. The Options may only be exercised in multiples of 10,000 on each occasion.
6.	Exercise Date	An Exercise Notice is only effective on and from the later of the date of receipt of the Exercise Notice and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (Exercise Date).
7.	Timing of issue of Shares on exercise	Within five Business Days after the Exercise Date, the Company will: <ul style="list-style-type: none"> (a) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Exercise Notice and for which cleared funds have been received by the Company; (b) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and (c) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options. <p>If a notice delivered under 7(b) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.</p>
8.	Shares issued on exercise	Shares issued on exercise of the Options rank equally with the then issued shares of the Company.
9.	Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the Optionholder will be varied to comply with the Listing Rules which apply to the reorganisation at the time of the reorganisation.

10.	Participation in new issues	There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options. However, the Company will give holders of the Options notice of the proposed issue prior to the date for determining entitlements to participate in any such issue.
11.	Change in exercise price/Adjustment for rights issue	<p>If the Company makes an issue of Shares pro rata to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment), the Exercise Price of an Option will be adjusted according to the following formula:</p> $\text{New exercise price} = O - \frac{E[P-(S+D)]}{N+1}$ <p>Where:</p> <p>O = the old Exercise Price of the Option.</p> <p>E = the number of underlying Shares into which one Option is exercisable.</p> <p>P = average market price per Share weighted by reference to volume of the Company's Shares during the 5 trading days ending on the day before the ex rights date or ex entitlements date of the relevant pro rata issue.</p> <p>S = the subscription price of a Share under the pro rata issue.</p> <p>D = the dividend due but not yet paid on the existing underlying Shares (except those to be issued under the pro rata issue).</p> <p>N = the number of Shares with rights or entitlements that must be held to receive a right to one Share.</p>
12.	Adjustment for bonus issues of Shares	<p>If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment):</p> <p>(a) the number of Shares or other securities which must be issued on the exercise of an Option will be increased by the number of Shares or other securities which the holder would have received if the holder had exercised the Option before the record date for the bonus issue; and</p> <p>(b) no change will be made to the Exercise Price.</p>
13.	Transferability	The Options will not be transferrable.

Your proxy voting instruction must be received by **11:00am (AEST) on Saturday, 20 June 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://portal.automic.com.au/investor/home> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

18 May 2026

Upcoming General Meeting of Shareholders

Dear Shareholder,


Firebrick Pharma Limited (ACN 157 765 896) (ASX: FRE) or “the **Company**”, advises that a General Meeting of Shareholders will be held by Virtual Meeting Facility using technology through an online meeting platform powered by Automic, on Monday, 22 June 2026 at 11.00am (AEST) (**Meeting**).

Notice of Meeting

The Notice of Meeting and Explanatory Statement (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company’s website at firebrickpharma.com/investors/ or the Company’s ASX market announcements platform at www.asx.com.au (ASX: FRE).

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth), Shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

Voting by Proxy

<p>Online scan the QR code below using your smartphone</p> 	<p>Lodge the Proxy Form online at https://investor.automic.com.au/#/loginsah by following the instructions:</p> <ol style="list-style-type: none">1. Login to the Automic website using the holding details as shown on your holding statement.2. Click on ‘View Meetings’ – ‘Vote’. <p>To use the online lodgement facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement.</p>
---	---

For further information on the online proxy lodgement process, or if you require a hard copy Proxy Form, please contact the Company’s Share Registry, Automic Registry Services (**Automic**), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Shareholder queries in relation to the Meeting

Shareholders can contact the Company Secretary with any questions prior to the meeting via email at cosec@firebrickpharma.com

Copies of all Meeting related material including the Notice are available to download from the Company’s website and the Company’s ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company’s website.

Authorised for ASX release by the Board of Firebrick Pharma Limited.